Lead Bookrunner on Perspective Therapeutics' Confidentially Marketed Public Offering

Oppenheimer & Co. Inc. January 23, 2024
Oppenheimer & Co. Inc. acted as Lead Bookrunner on Perspective Therapeutics’ $69MM Confidentially Marketed Public Offering

Perspective Therapeutics, Inc. (“Perspective”) (NYSEAM: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced on Thursday the pricing of its underwritten public offering of 132,075,218 shares of its common stock at a price of $0.37 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 30,086,944 shares at a price of $0.369 per pre-funded warrant. Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $60.0 million. Perspective granted the underwriters a 30-day option to purchase up to 24,324,324 additional shares of common stock at the public offering price, less underwriting discounts and commissions; the underwriters have exercised this option in full, resulting in a total offering size of $69.0 million.

Perspective recently announced it had begun recruitment for the second dosing cohorts in clinical studies for both of its lead programs: [212Pb]VMT-α-NET and [212Pb]VMT01. In addition, Perspective made two strategic announcements in early January: a co-development option arrangement with Lantheus Holdings for Perspective’s [212Pb]VMT-α-NET program which included a $28.0 million upfront payment, and an exclusive license agreement with Mayo Clinic for the rights to the PSMA Alpha-PET DoubLET platform technology for the treatment of PSMA-expressing cancers, with an initial focus on prostate.

Michael Margolis
Name:

Michael A. Margolis, R.Ph.

Title:

Senior Managing Director, Co-Head of Healthcare, Head of Healthcare Life Sciences

DISCLOSURES

This notice is provided for informational purposes only, and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.

This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.

2023 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 6282332.1